Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

Abstract

Malignant mesothelioma is an aggressive neoplastic proliferation derived from cells lining serosal membranes. The biological and clinical characteristics of epithelial type malignant mesothelioma are distinct from those of biphasic and sarcomatous type tumors. The goal of our study was to examine the molecular basis for this distinction. Microarray analysis confirmed that the molecular signatures of epithelial and biphasic histologic subtypes were distinct. Among the differentially expressed functional gene categories was the ubiquitin–proteasome pathway, which was upregulated in biphasic tumors. Cytotoxicity experiments indicated that 211H cells derived from biphasic tumors were synergistically sensitive to sequential combination regimens containing the proteasome inhibitor bortezomib and oxaliplatin. The mechanism of this synergistic response, which was not detected in cells of epithelial tumor origin, was apoptosis. Together, our results identify the ubiquitin–proteasome pathway as a biomarker of poor prognosis biphasic peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Adams J . (2003). Cancer Treat Rev 29 (Suppl 1): 3–9.

  • Adams J . (2004). Nat Rev Cancer 4: 349–360.

  • Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. (1999). Cancer Res 59: 2615–2622.

  • Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA . (2003). Am J Pathol 163: 1949–1960.

  • Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA . (2005a). Am J Respir Crit Care Med 172: 729–737.

  • Borczuk AC, Taub RN, Hesdorffer M, Hibshoosh H, Chabot JA, Keohan ML et al. (2005b). Clin Cancer Res 11: 3303–3308.

  • Fahy BN, Schlieman MG, Virudachalam S, Bold RJ . (2003). J Surg Res 113: 88–95.

  • Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C et al. (2003). J Clin Oncol 21: 349–354.

  • Gentiloni N, Febbraro S, Barone C, Lemmo G, Neri G, Zannoni G et al. (1997). J Clin Gastroenterol 24: 276–279.

  • Goldblum J, Hart WR . (1995). Am J Surg Pathol 19: 1124–1137.

  • Gordon GJ, Jensen RV, Hsiao L-L, Gullans SR, Blumenstock JE, Richards WG et al. (2003). J Natl Cancer Inst 95: 598–605.

  • Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP et al. (2005). Am J Pathol 166: 1827–1840.

  • Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP . (2003). Nucleic Acids Res 31: e15.

  • Khalil N, Parekh TV, O'Connor R, Antman N, Kepron W, Yehaulaeshet T et al. (2001). Thorax 56: 907–915.

  • Kim H, Xu G-L, Borczuk AC, Busch S, Filmus J, Capurro M et al. (2003). Am J Respir Cell Mol Biol 29: 694–701.

  • Kitagawa Y, Wong F, Lo P, Elliott M, Verburgt LM, Hogg JC et al. (1996). Am J Respir Cell Mol Biol 15: 45–54.

  • Lee JJ, Trizna Z, Hsu TC, Spitz MR, Hong WK . (1996). Cancer Epidemiol Biomarkers Prev 5: 191–197.

  • Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS et al. (2004). J Clin Oncol 22: 1706–1712.

  • Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K et al. (2006). Cancer Res 66: 2970–2979.

  • McShane LM, Radmacher MD, Freidlin B, Yu R, Li MC, Simon R . (2002). Bioinformatics 18: 1462–1469.

  • Mohamed F, Sugarbaker PH . (2002). Curr Treat Options Oncol 3: 375–386.

  • Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ . (2004). Mol Cancer Ther 3: 59–70.

  • Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D et al. (2002). Br J Cancer 87: 491–496.

  • Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D et al. (2004). Clin Cancer Res 10: 849–859.

  • Rajkumar SV, Richardson PG, Hideshima T, Anderson KC . (2005). J Clin Oncol 23: 630–639.

  • Reile H, Birnbock H, Bernhardt G, Spruss T, Schonenberger H . (1990). Anal Biochem 187: 262–267.

  • Ricotti L, Tesei A, De Paola F, Ulivi P, Frassineti GL, Milandri C et al. (2003). Clin Cancer Res 9: 900–905.

  • Robinson BW, Ostruszka L, Im MM, Shewach DS . (2004). Semin Oncol 31: 2–12.

  • Schenkein DP . (2005). Clin Lung Cancer 7 (Suppl 2): S49–S55.

  • Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B et al. (2003). Clin Lung Cancer 4: 294–297.

  • Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH . (2000). Br J Surg 87: 1587–1593.

  • Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J et al. (2003). Clin Cancer Res 9: 3080–3097.

  • Sugarbaker PH, Welch LS, Mohamed F, Glehen O . (2003). Surg Oncol Clin N Am 12: 605–621, xi.

  • Tallarida RJ . (2001). J Pharmacol Exp Ther 298: 865–872.

  • Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M . (2000). Curr Treat Options Oncol 1: 303–312.

  • Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. (2003). J Clin Oncol 21: 2636–2644.

  • Voorhees PM, Dees EC, O'Neil B, Orlowski RZ . (2003). Clin Cancer Res 9: 6316–6325.

Download references

Acknowledgements

This work was supported in part by the Columbia University Mesothelioma Center. Bortezomib was provided by Millennium.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C A Powell.

Additional information

Grant support: American Cancer Society CRTG00058.

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borczuk, A., Cappellini, G., Kim, H. et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26, 610–617 (2007). https://doi.org/10.1038/sj.onc.1209809

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209809

Keywords

This article is cited by

Search

Quick links